Zacks Company Profile for Enanta Pharmaceuticals, Inc. (ENTA : NSDQ) |
|
|
|
Company Description |
Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts.
Number of Employees: 131 |
|
|
|
Price / Volume Information |
Yesterday's Closing Price: $6.98 |
Daily Weekly Monthly
 |
20 Day Moving Average: 134,242 shares |
Shares Outstanding: 21.38 (millions) |
Market Capitalization: $149.21 (millions) |
Beta: 0.84 |
52 Week High: $17.24 |
52 Week Low: $4.09 |
Short Interest Ratio: |
|
% Price Change |
% Price Change Relative to S&P 500 |
4 Week |
-5.80% |
-9.33% |
12 Week |
36.86% |
15.12% |
Year To Date |
21.39% |
13.68% |
|
|
|
|
|
Address & Contact Information |
Street Address |
Phone / Fax |
Email Address |
Web URL |
4 KINGSBURY AVENUE - WATERTOWN,MA 02472 USA |
ph: 617-607-0800 fax: 617-607-0530 |
ir@enanta.com |
http://www.enanta.com |
|
|
|
General Corporate Information |
Officers
Jay R. Luly - President and Chief Executive Officer and Director
Paul J. Mellett - Chief Financial and Administrative Officer
Bruce L.A. Carter - Director
Mark G. Foletta - Director
Yujiro S. Hata - Director
|
|
Peer Information
Enanta Pharmaceuticals, Inc. (CORR.)
Enanta Pharmaceuticals, Inc. (RSPI)
Enanta Pharmaceuticals, Inc. (CGXP)
Enanta Pharmaceuticals, Inc. (BGEN)
Enanta Pharmaceuticals, Inc. (GTBP)
Enanta Pharmaceuticals, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 29251M106
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: September
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/04/25
|
|
Share - Related Items
Shares Outstanding: 21.38
Most Recent Split Date: (:1)
Beta: 0.84
Market Capitalization: $149.21 (millions)
|
|
|
|
|
|
EPS Information |
Dividend Information |
Analyst Coverage: No |
Dividend Yield: 0.00% |
Current Fiscal Quarter EPS Consensus Estimate: $-1.05 |
Indicated Annual Dividend: $0.00 |
Current Fiscal Year EPS Consensus Estimate: $-3.97 |
Payout Ratio: |
Number of Estimates in the Fiscal Year Consensus: 1.00 |
Change In Payout Ratio: |
Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
Next EPS Report Date: 08/04/25 |
|
|
|
|